April 2026 in “Portuguese Journal of Dermatology and Venereology” COVID-19 and its vaccines can cause various skin issues due to viral effects, immune responses, and stress.
March 2026 in “Frontiers in Medicine” New therapies for rare skin diseases show promise but need more research.
March 2026 in “American Journal of Clinical Dermatology” Dermatologists should respect Muslim patients' cultural and religious practices for better care.
March 2026 in “SKIN The Journal of Cutaneous Medicine” All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.
March 2026 in “Dermatology and Therapy” More severe alopecia areata can lower quality of life.
February 2026 in “International Journal of Clinical Pharmacy” Pharmacy care clinics can reduce some emergency visits by managing certain conditions and medication issues.
January 2026 in “Frontiers in Pharmacology” Minoxidil can treat hair loss with topical, oral, and sublingual options, offering personalized choices.
January 2026 in “Dermatology and Therapy” Poor sleep may lead to hair loss, and hair loss may affect sleep.
January 2026 in “SKIN The Journal of Cutaneous Medicine” Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.
January 2026 in “Frontiers in Medicine” Alopecia areata in Taiwan has a high disease burden and needs better research and diagnostic criteria.
January 2026 in “Dermatology Online Journal” Scalp cooling is cost-effective for reducing hair loss from chemotherapy and should be covered by insurance.
January 2026 in “Dermatology Online Journal” Female-marketed minoxidil foam is more expensive than male-marketed, but generic and bulk options can reduce this gap.
November 2025 in “Open Repository of the University of Porto (University of Porto)” Minoxidil and spironolactone can improve hair growth, but responses vary and side effects are common.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in nasal, genital, and beard areas for severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in teens with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Alopecia areata negatively affects self-esteem, relationships, and academics in young people.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib works better in adolescents than adults for treating severe alopecia areata.
October 2025 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in health literacy and patient care.
September 2025 in “Dermatology and Therapy” Baricitinib is a promising treatment for alopecia areata in the UAE, but there are challenges with data and access.
September 2025 in “Tạp chí Da liễu học Việt Nam” Combining oral methylprednisolone with microneedle radiofrequency improves hair growth in alopecia areata but may cause pain and side effects.
August 2025 in “PLoS ONE” Improving access to hidradenitis suppurativa care can reduce social disparities.
July 2025 in “UCP Journal of Science & Technology” Certain blood and kidney tests can indicate pregnancy.
April 2025 in “PharmacoEconomics - Open” Patients with Alopecia Areata are willing to trade life duration for better quality of life.
March 2025 in “Institutional Repositories DataBase (IRDB)” The testes significantly contribute to vitamin D metabolism and may affect male reproductive health and conditions like hair loss.
March 2025 in “Journal of Endocrinology and Metabolism” Rodent models of PCOS show some hormone changes similar to humans, but also have key differences.
January 2025 in “Вопросы современной педиатрии” Janus kinase inhibitors effectively treat alopecia areata but may cause relapses and have long-term safety concerns.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is widely used for several conditions, especially COVID-19, but its safety and effectiveness are still being evaluated.
September 2024 in “Cutis” Dermatology residency programs need better DEI training to improve care for diverse patients.